Skip to main content
logo
Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
1,109.94
+39.78 (3.72%)
At close: Nov 25, 2025, 4:00 PM EST
1,109.78
-0.16 (-0.01%)
After-hours: Nov 25, 2025, 7:59 PM EST

Eli Lilly Revenue by Segment

Period EndingSep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016
Diabetes
42.84B37.06B33.24B29.52B26.16B23.47B20.97B19.67B
Diabetes Growth
63.74%57.90%58.49%50.10%46.17%39.40%37.36%35.97%
Oncology
9.32B9.14B8.89B8.75B8.08B7.60B7.11B6.66B
Oncology Growth
15.29%20.33%24.99%31.45%25.83%27.27%25.46%17.51%
Immunology
5.00B4.82B4.65B4.39B4.21B4.01B3.85B3.80B-
Immunology Growth
18.79%20.28%20.59%15.68%15.98%14.30%14.21%13.54%-
Animal Health
---------------------------3.14B3.12B3.08B3.08B3.09B3.13B3.10B3.17B
Animal Health Growth
---------------------------1.84%-0.49%-0.42%-3.01%-2.30%---
Cardiovascular
---------------------------2.25B2.54B2.62B2.74B2.87B3.04B3.15B3.17B
Cardiovascular Growth
----------------------------21.74%-16.63%-17.04%-13.66%-10.98%---
Neuroscience
1.32B1.36B1.36B1.47B1.44B2.86B2.91B2.88B
Neuroscience Growth
-8.19%-52.40%-53.34%-48.81%-50.26%89.84%92.66%86.18%
Other
942.20M867.80M873.90M902.90M968.50M981.80M1.09B1.12B
Other Growth
-2.72%-11.61%-19.74%-19.54%-20.74%-41.97%-41.83%-68.12%

Revenue by Geography

Period EndingSep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016
United States
39.64B36.15B33.17B30.38B27.80B25.35B23.05B21.79B
United States Growth
42.58%42.58%43.91%39.39%39.03%33.10%32.07%19.80%
Europe
10.91B9.04B7.87B6.92B5.81B6.75B6.52B6.17B
Europe Growth
87.76%33.91%20.61%12.08%-1.71%53.44%50.93%43.62%
Rest of World
4.93B4.35B4.38B4.27B3.95B3.62B3.17B2.95B
Rest of World Growth
24.78%20.08%38.20%44.97%30.64%25.97%14.14%3.30%
Japan
2.04B1.91B1.85B1.81B1.69B1.66B1.65B1.67B
Japan Growth
20.18%15.38%12.34%8.50%4.06%-4.00%-4.35%-4.28%
China
1.91B1.81B1.74B1.66B1.61B1.54B1.54B1.54B----------------
China Growth
18.52%17.31%12.43%7.83%6.28%5.01%8.75%5.98%----------------

Operating Expense Breakdown

Period EndingSep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016
Research and Development
12.56B11.83B11.20B10.99B10.53B10.21B9.85B9.31B
Research and Development Growth
19.25%15.88%13.71%18.01%20.40%25.37%30.21%29.52%
Marketing, Selling, and Administrative
10.39B9.75B9.11B8.59B8.09B7.80B7.61B7.40B
Marketing, Selling, and Administrative Growth
28.33%24.98%19.78%16.08%13.65%12.49%14.69%14.95%
Acquired In-Process Research and Development
2.57B4.74B4.74B3.28B3.71B3.86B3.81B3.80B-------
Acquired In-Process Research and Development Growth
-30.79%22.75%24.61%-13.67%8.68%665.46%348.79%318.25%-------
Impairment, Restructuring, and Other
825.50M-895.60M867.37M561.47M686.37M-355.87M---560.70M492.50M-------
Impairment, Restructuring, and Other Growth
20.27%-151.66%54.69%14.00%77.17%-3.81%---98.20%-33.17%-------
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.